DANIEL CHIU: Open Payments
NPI 1427419530 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,584 in 172 payments from 20 companies in 2025. Trend: 2023 $3,440 · 2024 $3,666 · 2025 $3,584
Food & beverage: $3,500Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 47 | $814 |
| Janssen Biotech, Inc. | 23 | $468 |
| Madrigal Pharmaceuticals | 16 | $426 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $303 |
| Ardelyx, Inc. | 9 | $232 |
| GENZYME CORPORATION | 6 | $194 |
| QOL Medical, LLC | 5 | $142 |
| PFIZER INC. | 7 | $138 |
| Aimmune Therapeutics, Inc. | 7 | $136 |
| Phathom Pharmaceuticals, Inc. | 7 | $124 |
Products named: RINVOQ, TREMFYA, REZDIFFRA, IBSRELA, DUPIXENT, XIFAXAN, SKYRIZI, Sucraid.
Industry payments across CA — which companies pay providers there.
